Human monoclonal antibodies for the treatment and prevention of hepatitis C virus infection

用于治疗和预防丙型肝炎病毒感染的人单克隆抗体

• 批准号: G0801169/1
• 负责人: Jonathan Ball
• 金额: $ 68.66万
• 依托单位: University of Nottingham
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2009
• 资助国家: 英国
• 起止时间: 2009 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0801169%2F1
• 关键词: Human; monoclonal; antibodies; treatment; prevention

Chronic Hepatitis C virus is a blood-borne infection that can result in development of very serious liver disease. The most severe forms of liver disease can only be treated by liver transplantation. Re-infection of the transplanted liver is often rapid and current treatments are ineffective in this group of patients. Alternative therapies are sought, particularly for this group of patients. Therefore, we will isolate human monoclonal antibodies from individuals who have naturally cleared virus. These antibodies will provide important lead therapies to prevent transplant re-infection and will also provide important information that will help vaccine design. An important aspect of this work will be to study how the virus changes during infection, so that those antibodies that target the widest range of virus strains are identified.

慢性丙型肝炎病毒是一种血液传播的感染，可导致非常严重的肝脏疾病的发展。最严重的肝病只能通过肝移植治疗。移植肝脏的再感染通常很快，目前的治疗对这组患者无效。寻求替代疗法，特别是对这类患者。因此，我们将从自然清除病毒的个体中分离出人单克隆抗体。这些抗体将提供重要的先导疗法，以防止移植再感染，也将提供有助于疫苗设计的重要信息。这项工作的一个重要方面将是研究病毒在感染过程中如何变化，以便确定那些针对最广泛病毒株的抗体。